by Truveta Research | Jul 16, 2025 | Research, Research Insights
The proportion of patients initiating treatment for multiple sclerosis (MS) with a high efficacy disease-modifying therapy (DMT) more than doubled from 2018 to 2025, reflecting evolving clinical guidelines. Use of oral and injectable therapies showed a gradual decline...
by Truveta Research | Jun 23, 2025 | Research, Research Insights
Switching from bio-originator Humira to a biosimilar peaked in April 2024 – the month an important formulary change took effect – and remains higher than 2023, suggesting growing adoption of biosimilars. More than 1 in 8 patients who initiated a biosimilar...
by Truveta staff | Mar 20, 2025 | Data
Why autoimmune research needs better real-world data Biologics like Humira, Enbrel, and Rinvoq have transformed autoimmune treatment, revolutionizing treatment for patients with chronic inflammatory infections. However, the traditional methods of studying these...
by Truveta Research | Aug 6, 2024 | Research, Research Insights
Authors: Patricia J. Rodriguez, PhD MPH ⊕Truveta, Inc, Bellevue, WA, Brianna M. Goodwin Cartwright ⊕Truveta, Inc, Bellevue, WA, Samuel Gratzl PhD ⊕Truveta, Inc, Bellevue, WA, Charlotte Baker DrPH MPH CPH ⊕Truveta, Inc, Bellevue, WA, Nicholas Stucky, MD PhD ⊕Truveta,...
by Truveta Research | Nov 2, 2023 | Research, Research Insights
Adalimumab (Humira) and etanercept (Enbrel) are high-cost specialty medications used to treat a variety of autoimmune diseases. Medication adherence is often influenced by social drivers of health, so we aimed to measure adherence using the proportion of days covered...
